Paediatric management of endocrine complications in McCune-Albright syndrome

Journal of Pediatric Endocrinology and Metabolism

Volumn 18, Issue 1, 2005, Pages 33-41

  Zacharin, Margaret ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Acromegaly; Fibrous dyplasia; Gonadotrophin independent precocious puberty; McCune Albrigth syndrome; Octreotide LAR

Indexed keywords

ANASTROZOLE; FLUTAMIDE; FOLLITROPIN; GONADOTROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; OCTREOTIDE; PAMIDRONIC ACID; SOMATOMEDIN C; TESTOLACTONE; TESTOSTERONE;

ACNE; ACROMEGALY; ADOLESCENCE; AGE DISTRIBUTION; ALBRIGHT SYNDROME; ARTICLE; BONE AGE; BONE PAIN; CAFE AU LAIT SPOT; CALVARIA; CASE REPORT; DRUG EFFICACY; DRUG RESPONSE; ENDOCRINE DISEASE; ENDOCRINE SURGERY; FACIES; FOLLITROPIN BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; GROWTH INHIBITION; GROWTH RATE; HAIR GROWTH; HUMAN; HYPOPHYSIS; JAW; LEG FRACTURE; LIVER TOXICITY; LONG TERM CARE; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRECOCIOUS PUBERTY; PROTEIN BLOOD LEVEL; PUBERTY; QUALITY OF LIFE; RADIOTHERAPY; SCHOOL CHILD; SHORT COURSE THERAPY; SPHENOID; SWEAT GLAND DISEASE; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; TOOTH DISEASE; VISUAL FIELD DEFECT;

EID: 13644254142     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2005.18.1.33     Document Type: Article

References (36)

1. Weinstein LS, Shenker A, Gejman PV, Merino MJ. Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome N Engl J Med 1991; 325: 1688-1695.
2. s. J Paediatr 1993; 123: 509-518.
3. Zacharin M, O'Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with McCune Albright syndrome J Paediatr 2000; 137: 403-409.
4. Yavuzer R. Khilnani R. Jackson IT, Audet B. A case of atypical McCune-Albright syndrome requiring optic nerve decompression. Ann Plastic Surg 1999; 43: 430-435.
5. Lane JM, Khan SN, O'Connor WJ, Nydick M, Hommen JP, Schneider R, Tomin E, Brand J, Curtin J. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Related Res 2001; 38: 6-12.
6. Isaia GC, Lala R, Defilippi C, Matarazzo, P, Andreo M, Roggia C, Priolo G, de Sanctis C. Bone turnover in children and adolescents with McCune Albright syndrome treated with pamidronate for bone fibrous dysplasia. Calcif Tissue Int 2002; 71: 121-128.
7. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux F. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 2003; 88: 4569-4575.
8. Pfeilschifter J, Ziegler R. Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune Albright syndrome. Med Klin 1998; 93: 352-359.
9. Chapurlat R, Meunier PJ. Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis. Revue de Chirurgie Orthopedique et Reparatrice de 1 Appareil Moteur 1998; 84: 743-751.
10. Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997; 12: 1746-1752.
11. Chapurlat R, Delmas PD, Meunier PJ. Extended follow-up of patients with fibrous dysplasia of bone treated with pamidronate. Bone 1998; 22 (Suppl): Abstr B43.
12. Chapurlat R, Meunier PJ. The non surgical treatment of fibrous dysplasia. Rev Rheum (Engl Ed) 1999; 66: 1-3.
13. Lee JS, Fitzgibbon E, Butman JA, Dufresne CR, Kushner H, Wientroub S, Robey PG, Collins MT. Normal vision despite narrowing of the optic canal in fibrous dysplasia N Engl J Med 2002; 347: 1670-1676.
14. Scheithauer BW, Kovacs KT, Stefaneanu L, Horvath E, Kane LA, Young WF, Lloyd RV, Randall R, Davis DH. The pituitary in gigantism. Endocr Pathol 1995; 6: 173-187.
15. Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985; 313: 1576-1580.
16. Lamberts SWJ. Uitterlinden P, Del Pozo E. Sandostatin (SMS201-995) induces a continuous further decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab 1987; 65: 703-710.
17. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with somatostatin analog octreotide. Arch Intern Med 1991; 151: 1573-1578.
18. Feuillan PP, Jones J, Ross JL. Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog. J Clin Endocrinol Metab 1995; 80: 1357-1360.
19. Sherman SI, Ladenson PW. Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J Endocrinol Invest 1992; 15: 185-190.
20. Chanson P, Dib A, Visot A, Derome PJ. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. Eur J Endocrinol 1994; 131: 229-234.
21. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, LeRoith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT. Characterization of gsp-mediated growth hormone excess in the context of McCune Albright syndrome. J Clin Endocrinol Metab 2002; 87: 5104-5112.
22. Cremonini N, Graziano E, Chiarini V, Sforza A, Zampa GA. Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995-bromocriptine combined treatment results. J Clin Endocrinol Metab 1992; 75: 1166-1169.
23. Coutant R, Lumbroso S, Rey R, Lahlou N, Venara M, Rouleau S, Sultan C, Limal JM. Macroorchidism due to autonomous hyperfunction of Sertoli cells and G(s)alpha gene mutation: an unusual expression of McCune Albright syndrome in a prepubertal boy. J Clin Endocrinol Metab 200 1; 86: 1778-1781.
24. de Sanctis C, Lala R, Matarazzo P, Balsamo A, Bergamaschi R, Cappa M, Cisternino M, de Sanctis V, Lucci M, Franzese A, Ghizzoni L, Pasquino AM, Segni M, Rigon F, Saggese G, Bertelloni S, Buzi F. McCune-Albright syndrome: a longitudinal clinical study of 32 patients. J Paediatr Endocrinol Metab 1999; 12: 817-826.
25. Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A, Malley JD, Barnes K, Loriaux DL, Cutler GB Jr. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986; 315; 1115-1119.
26. Eugster E, Rubin S, Reiter E, Plourde P, Jou HC, Pescovitz O. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a muticenter trial. J Pediatr 2003; 143: 60-66.
27. Roth C, Freiberg C, Zappel H, Albers N. Effective aromatase inhibition by anastrazole in a patient with gonadotrophin independent precocious puberty in McCune-Albright syndrome. J Paediatr Endocrinol Metab 2002; 15 (Suppl 3): 945-948.
28. Candeliere GA, Glorieux FH, Prud'Homme J, St-Arnaud R. Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 1995; 332: 1546-1577.
29. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 1996; 98: 30-35.
30. Ruggieri P, Sim FH, Bone JR, Unni KK. Malignancies in fibrous dysplasia. Cancer 1994; 73: 1411-1424.
31. Cohen MM Jr. Fibrous dysplasia is a neoplasm. Am J Med Genet 2001; 98: 290-293.
32. Jenkins PJ, Fairclough PD. Colorectal neoplasia in acromegaly. Clin Endocrinol 2001; 55: 727-729.
33. Bustin SA, Jenkins PJ. The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends Mol Med 2001; 7: 447-454.
34. Rosen LS, Gordon D, Antonio BS, Kaminski M, Howell A, Belch A, Mackey JA, Apffelstaedt J, Tfrin M, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
35. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593.
36. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anti-Cancer Drugs 2001; 12: 459-465.